Dr Debra Patt on Capturing the HER2-Low Population
Recognizing HER2-low patients as distinct requires proper evaluation to identify and treat them differently from HER2-positive or -negative patients.
Care Advancements
American Journal of Managed Care
July 24, 2022
Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology.
